Lifestyle & Food               Voorkomen is het nieuwe genezen               Health Valley EventLuc Sterkman   13 maart 2013
Nelissen Pluimvee
Globus ei BV
Prijsvorming                 1,4Prijs per kilo                 1,2                  1                 0,8                 ...
Zoektocht naar toegevoegde waarde
Begin van nieuw leven!
Preventie         Genetica            Voeding                      Leefstijl    Gezondheidszorg
Health Valley 2013Health Valley, make health & innovation work!
Innovatie
Innovatie 2.0
Medication       NutraceuticalFood
Ontwikkelprogramma’sNWT-02           Bioactive peptidesNWT-03     Behoud van cardiovasculaire           gezondheidOBESITAS
Pharmaceutical approach Aangepast op regelgeving Senior farma medewerkers Klinische studies Product ontwikkeling Kwaliteit...
New regulation (2006/1924/EC)Voedingsclaims                   Gezondheidsclaims                             Art. 13       ...
Business model
Egg yolk is the superior carrier for lutein          Chung, HY, et al, J. Nutr. 134:1887-1893, 2004
NWT-02 status              2007                                                      2012                         2014    ...
Clinical trial program  Human 1 - pivotal study on visual function  12 months | 100 subjects with early stage AMD  Human 2...
NWT-02 results – pilot study                                    Blood lutein level                                        ...
Results  NWT-02 does very efficiently bring lutein and other valuable  nutrients in the blood stream and into the macula. ...
NWT-03: “the new approachfor maintaining (vascular) health”Development of bioactive peptides as functional food or nutrace...
NWT-03 Project Hydrolysate – produced via enzymatic treatment of lysozyme, an egg- derived protein Designed based on bioin...
NWT-03 status              2006                                                       2012                       2015  Pat...
Acute effects of NWT-03 in SHR-rats
Kidney – anatomy and histology                             Histology (PAS) of a                             healthy glomer...
Renal morphology in ZDF-rats
Glomerulosclerosis and Albuminuria                           60                           50glomerulosclerosis-score      ...
Sector overschrijdende aanpak         Genetica                                   Wetenschap                               ...
Preventieve aanpak                         Diagnostiek         Genetica                                   Wetenschap      ...
Secundaire preventie  Vroege diagnostiek         Medische technologie  – Kan leiden tot                             – Kan ...
Rol Newtricious
Samenwerken
Samenwerken en verbinden
Virtual company
Newtricious “Network”                        Nateland consultancy                    Coppelmans VOF
BrandRepAroma Uden
Strategische investeerders
Luc Sterkman
Luc Sterkman
Luc Sterkman
Luc Sterkman
Luc Sterkman
Luc Sterkman
Luc Sterkman
Luc Sterkman
Luc Sterkman
Luc Sterkman
Upcoming SlideShare
Loading in …5
×

Luc Sterkman

220
-1

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
220
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Luc Sterkman

  1. 1. Lifestyle & Food Voorkomen is het nieuwe genezen Health Valley EventLuc Sterkman 13 maart 2013
  2. 2. Nelissen Pluimvee
  3. 3. Globus ei BV
  4. 4. Prijsvorming 1,4Prijs per kilo 1,2 1 0,8 2003 2004 2005 0,6 0,4 0,2 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 Week
  5. 5. Zoektocht naar toegevoegde waarde
  6. 6. Begin van nieuw leven!
  7. 7. Preventie Genetica Voeding Leefstijl Gezondheidszorg
  8. 8. Health Valley 2013Health Valley, make health & innovation work!
  9. 9. Innovatie
  10. 10. Innovatie 2.0
  11. 11. Medication NutraceuticalFood
  12. 12. Ontwikkelprogramma’sNWT-02 Bioactive peptidesNWT-03 Behoud van cardiovasculaire gezondheidOBESITAS
  13. 13. Pharmaceutical approach Aangepast op regelgeving Senior farma medewerkers Klinische studies Product ontwikkeling Kwaliteits standaard – Good Clinical Practice – Good Laboratory Practice – Good Manufacturing Practice
  14. 14. New regulation (2006/1924/EC)Voedingsclaims Gezondheidsclaims Art. 13 Art. 14 Art. 13.1 Art. 13.5 Art. 14Bijv. Nutriëntsamenstelling Algemeen Claim op basis - Risico reductie geaccepteerd van ‘nieuw’ - Kinderen wetenschap- bewijs pelijk bewijs
  15. 15. Business model
  16. 16. Egg yolk is the superior carrier for lutein Chung, HY, et al, J. Nutr. 134:1887-1893, 2004
  17. 17. NWT-02 status 2007 2012 2014 PCT National Patents EU filing PCT filing grant authorizations ed EFSA/Regulatory Lab Volunteers People “at risk’’ FDAProduction Lab scale Pilot scale Industrial MarketMarketing definition Product definition Preparations Partnering Sales
  18. 18. Clinical trial program Human 1 - pivotal study on visual function 12 months | 100 subjects with early stage AMD Human 2 - study on cholesterol & AMD 3 months | 120 healthy volunteers Human 3 - study on bioavailability of ‘EyePowder’ formulations vs NWT-02 2 months | 100 healthy volunteers Human 4 - pivotal study on visual function 12 months | 120 subjects - early stage AMD
  19. 19. NWT-02 results – pilot study Blood lutein level Total Cholesterol 2,00 1,04 1,03 1,80 1,02 Change vs base line Change vs base line Normal egg Normal egg 1,60 1,01 NWT-02 NWT-02 1,00 1,40 NWT-01 (lutein 0,99 NWT-01 (lutein egg) egg) 1,20 Control 0,98 Control 0,97 1,00 0,96 0,80 0,95 0w 6,5 w 13 weeks 0w 6,5 w 13 weeks Time Time
  20. 20. Results NWT-02 does very efficiently bring lutein and other valuable nutrients in the blood stream and into the macula. This leads to stabilization (often even improvement) of eye functions such as visual acuity and light- dark adaptation. Although egg yolk is used, there is no or little effect on blood cholesterol.
  21. 21. NWT-03: “the new approachfor maintaining (vascular) health”Development of bioactive peptides as functional food or nutraceutical forthe prevention of vascular damage and related disorders
  22. 22. NWT-03 Project Hydrolysate – produced via enzymatic treatment of lysozyme, an egg- derived protein Designed based on bioinformatics-model of the University Wageningen; aiming for a beneficial effect on the arterial vascular wall First tested in pharmacology models to confirm the effect and elucidate the mechanisms Subsequently tested in animal experiments: – Confirming reduction in bloodpressure in Hypertensive rats – Demonstrating maintenance of the flexibility of the vascular wall in ZDF-rats, which suffer from Diabetes melllitus; model for ageing
  23. 23. NWT-03 status 2006 2012 2015 Patents PCT National EU filing PCT filing granted authorizations Regulatory Lab Animals Volunteers Patients EFSA/ FDA Production Lab scale Pilot scale Industrial Market Marketing definition Product definition Preparations Partnering Sales
  24. 24. Acute effects of NWT-03 in SHR-rats
  25. 25. Kidney – anatomy and histology Histology (PAS) of a healthy glomerulus
  26. 26. Renal morphology in ZDF-rats
  27. 27. Glomerulosclerosis and Albuminuria 60 50glomerulosclerosis-score 40 9 controls 30 8 diabetes Albuminurie (mg/24uur) 7 diabetes + NWT-03 20 6 controles 10 5 diabetes 4 diabetes + NWT-03 0 3 2 1 0
  28. 28. Sector overschrijdende aanpak Genetica Wetenschap Innovatieve bedrijven Voeding Leefstijl Overheid Gezondheidszorg
  29. 29. Preventieve aanpak Diagnostiek Genetica Wetenschap Innovatieve bedrijven Voeding Speciale voeding Leefstijl Overheid Preventiemanagement Gezondheidszorg Zorgverzekeraars
  30. 30. Secundaire preventie Vroege diagnostiek Medische technologie – Kan leiden tot – Kan leiden tot Vroege behandeling Diagnostische apparatuur – Met als doel – Met als doel Secundaire preventie Vroege diagnostiek – Gebruik makend van – Gebruik makend van Food Scanning Laser Optics – Milde effecten – Milde methode – Zonder neven effecten – Zonder neven effecten – Op professionele wijze – Op professionele wijze ontwikkeld (farma) ontwikkeld (Qserve)
  31. 31. Rol Newtricious
  32. 32. Samenwerken
  33. 33. Samenwerken en verbinden
  34. 34. Virtual company
  35. 35. Newtricious “Network” Nateland consultancy Coppelmans VOF
  36. 36. BrandRepAroma Uden
  37. 37. Strategische investeerders

×